Display Settings:

Format

Send to:

Choose Destination
    Cancer Res. 2007 Jan 1;67(1):5-8.

    Perspectives of gammadelta T cells in tumor immunology.

    Source

    Institute of Immunology, University Hospital Schleswig-Holstein Campus Kiel, Michaelisstrasse 5, D-24105 Kiel, Germany. kabelitz@immunologie.uni-kiel.de

    Abstract

    Subsets of human gammadelta T cells recognize tumor cell-expressed ligands that are not seen by the T-cell receptor of conventional alphabeta T cells. Vdelta1 T cells recognize MHC class I chain-related molecules A and B and UL-16-binding proteins expressed at variable levels on epithelial tumor cells and some leukemias and lymphomas. In addition, therapeutically used aminobisphosphonates and synthetic phosphoantigens activate Vdelta2 T cells, the dominant subset of gammadelta T cells in human peripheral blood that display strong cytotoxicity towards various epithelial tumors. Intentional activation of gammadelta T cells in vivo and/or adoptive cell therapy with in vitro expanded gammadelta T cells holds considerable promise as a novel immunotherapy in certain types of cancer.

    PMID:
    17210676
    [PubMed - indexed for MEDLINE]
    Free full text

      Supplemental Content

      Icon for HighWire Press

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk